Steve Dodson

Steve Dodson has a diverse work experience in the pharmaceutical industry. Steve is currently serving as the Senior Vice President of Pharmacology & Nonclinical Development at Aeovian Pharmaceuticals since November 2022. Prior to this, from October 2018 to October 2022, they held the position of Senior Vice President of Discovery Pharmacology at CODA Biotherapeutics.

In their earlier roles, Steve worked as the Senior Director of Drug Discovery and Development at Second Genome Inc. from 2014 to 2018, where they were responsible for discovery, non-clinical, and early clinical development. Before that, they served as the Head of Integrated Services at Synterys, Inc. in 2013 and as the Co-founder of Myotherix, Inc., a pharmaceutical company focused on treating muscular dystrophies and cardiomyopathies.

Steve also has experience as the Director of Drug Discovery/Drug Development at Neuro Therapeutics Pharma, Inc. from 2010 to 2013 and as the Director of Molecular Pharmacology at Renovis, Inc., a subsidiary of Evotec AG, from 2002 to 2009. At Renovis, they led a molecular pharmacology group and was involved in multiple drug discovery programs in neuropathic pain, CNS disorders, and inflammatory diseases.

Earlier in their career, Steve worked as a Content Scientist/Product Manager at Ingenuity from 1999 to 2001.

Overall, Steve Dodson has held various leadership positions and has extensive experience in pharmacology, drug discovery, and development within the pharmaceutical industry.

Steve Dodson earned a Bachelor of Science degree in Genetics from the University of California, Berkeley, between 1986 and 1990. Steve then pursued further education at Stanford University, where they obtained a Ph.D. in Biological Sciences from 1992 to 1999.